Name | Alendronic Acid |
Synonyms | ABDP ALENDRONATE Alendronic Acid ALENDRONIC ACID a-hydroxy-d-aminobutylidenediphosphonic acid (4-AMINO-1-HYDROXYBUTYLIDENE)DIPHOSPHONIC ACID (4-amino-1-hydroxybutylidene)bis-phosphonicaci (4-Amino-1-hydroxybutylidene)bisphosphonic acid 4-AMINO-1-HYDROXY-1,1-BUTYLIDINEDIPHOSPHONIC ACID (4-AMINO-1-HYDROXYBUTYLIDENE)-BIS-(PHOSPHONIC ACID) 4-amino-1-hydroxybutylidene-1,1-bis(phosphonicacid) (4-AMINO-1-HYDROXY-1-PHOSPHONOBUTYL)PHOSPHONIC ACID |
CAS | 66376-36-1 |
EINECS | 204-352-8 |
InChI | InChI=1/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12) |
Molecular Formula | C4H13NO7P2 |
Molar Mass | 249.1 |
Density | 1.857±0.06 g/cm3(Predicted) |
Melting Point | 230-235°C |
Boling Point | 616.7±65.0 °C(Predicted) |
Water Solubility | Insoluble in water |
Appearance | powder to crystal |
Color | White to Light yellow |
Merck | 14,229 |
pKa | pK1 2.72 ±0.05; pK2 8.73 ±0.05; pK3 10.5 ±0.1; pK4 11.6 ±0.1 at 25°, (0.1M KCl) |
Storage Condition | Room Temprature |
MDL | MFCD00868112 |
Physical and Chemical Properties | Fine white powder, melting point 233~235 C (decomposition). pKl 2.72±0.05;pK2 8.73±0.05;pK3 10.5±0.1;pK4 11.6±0.1(2512,0.1mol/L potassium chloride). |
In vitro study | Bisphosphonates are widely used in the treatment of osteoporosis, and among the bisphosphonates, alendronic acid is the most frequently prescribed drug. Bisphosphonates have powerful inhibitory effects on bone remodeling, a process that is critically important for fracture healing. |
UN IDs | 1759 |
RTECS | SZ6521833 |
Hazard Class | 8 |
Packing Group | III |
fine white powder, melting point 233-235 ° C. (decomposition).
In 4-aminobutyric acid and phosphoric acid, phosphorus trihalide was added dropwise for reaction. When the reactants had hardened, they were heated again, water was added for hydrolysis, and after cooling, methanol was added and alendronic acid was collected.
alendronate sodium was previously developed by isitutogentili, Italy, and later transferred to Merck, USA, for continued development and Merck, Inc. for development. It was first launched in Italy in 1993. Bisphosphonate inhibitors of bone resorption. For the treatment of osteoporosis.